David Gusick is the founder of Somebody To Talk To, a program bringing patients, caregivers, and doctors together for free weekly sessions. With 30+ years in systems architecture and entrepreneurship, he is building a global support model to improve quality of life for rare disease patients.

Fear, pain, and uncertainty can feel overwhelming with amyloidosis. But avoiding them often makes them worse. In this session, you’ll learn simple, practical techniques to face challenges head-on, reduce emotional stress, and regain a sense of control so you can move forward with more confidence each day.

CAR-T therapy is emerging as a potential future option for AL amyloidosis. In this session, Heather Landau reviews the latest CAR-T developments, how it works, who may be eligible, current trial data, and what AL patients should realistically know today versus what’s still ahead.

Dr. Landau works as part of a multidisciplinary care team for patients with hematologic disorders. She has a special interest and expertise in treating patients with disorders that arise in white blood cells called plasma cells, including multiple myeloma and light chain (AL) amyloidosis.